1.Clinical Outcome of Endoscopic Submucosal Dissection for Papillary Type Early Gastric Cancer: A Multicenter Study
Hyun-Deok SHIN ; Ki Bae BANG ; Sun Hyung KANG ; Hee Seok MOON ; Jae Kyu SUNG ; Hyun Yong JEONG ; Dong Kyu LEE ; Ki Bae KIM ; Sun Moon KIM ; Seung Woo LEE ; Dong Soo LEE ; Young Sin CHO ; Il-Kwun CHUNG ; Ju Seok KIM
Gut and Liver 2024;18(3):426-433
Background/Aims:
Papillary adenocarcinoma is classified to differentiated-type gastric cancer and is indicated for endoscopic submucosal dissection. However, due to its rare nature, there are limited studies on it. The purpose of this study was to determine the outcome of endoscopic submucosal dissection in patients with papillary-type early gastric cancer and to find the risk factors of lymph node metastasis.
Methods:
Patients diagnosed with papillary-type early gastric cancer at eight medical centers, who underwent endoscopic submucosal dissection or surgical treatment, were retrospectively reviewed. The clinical results and long-term outcomes of post-endoscopic submucosal dissection were evaluated, and the risk factors of lymph node metastasis in the surgery group were analyzed.
Results:
One-hundred and seventy-six patients with papillary-type early gastric cancer were enrolled: 44.9% (n=79) in the surgery group and 55.1% (n=97) in the endoscopic submucosal dissection group. As a result of endoscopic submucosal dissection, the en bloc resection and curative resection rates were 91.8% and 86.6%, respectively. The procedure-related complication rate was 4.1%, and local recurrence occurred in 3.1% of patients. Submucosal invasion (odds ratio, 3.735; 95% confidence interval, 1.026 to 12.177; p=0.047) and lymphovascular invasion (odds ratio, 7.636; 95% confidence interval, 1.730 to 22.857; p=0.004) were the risk factors of lymph node metastasis in papillary-type early gastric cancer patients.
Conclusions
The clinical results of endoscopic submucosal dissection in papillary-type early gastric cancer were relatively favorable, and endoscopic submucosal dissection is considered safe if appropriate indications are confirmed by considering the risk of lymph node metastasis.
2.Targeting Risk Factors for the Control of Central Line-Associated Bloodstream Infection in the Neonatal Intensive Care Unit: A Single Tertiary Center Experience
Jiyoon JEONG ; Yoojin KWUN ; Min-ju KIM ; Sang-Ho CHOI ; Euiseok JUNG ; Byong Sop LEE ; Ki-Soo KIM ; Ellen Ai-Rhan KIM
Neonatal Medicine 2021;28(3):116-123
Purpose:
The aim of this study was to estimate the effect of targeting risk factors for the control of central line-associated bloodstream infection (CLABSI) among high-risk infants in a tertiary neonatal intensive care unit (NICU).
Methods:
Infants admitted to the NICU and diagnosed with CLABSI from January to December 2013 were eligible for inclusion to the study. The CLABSI group (n=47) was matched in a 1:2 ratio to the control group (n=94) based on gestational age, birth weight, and Score for Neonatal Acute Physiology-II. Risk factors for CLABSI were identified using the Cox proportional hazard model, and analysis of the effect of these risk factors targeting infection control was performed.
Results:
The risk factors associated with CLABSI were prolonged central line dwell days (adjusted hazard ratio [HR], 1.028; 95% confidence interval [CI], 1.011 to 1.045; P=0.001), use of a silicone catheter (adjusted HR, 5.895; 95% CI, 1.893 to 18.355; P=0.002), surgical treatment (adjusted HR, 3.793; 95% CI, 1.467 to 9.805; P=0.006), and less probiotic supplementation (adjusted HR, 0.254; 95% CI, 0.068 to 0.949; P=0.042). By targeting these risk factors with a quality improvement initiative, the mean CLABSI incidence rate per 1,000 catheter-days decreased from 6.6 to 3.1 (P=0.004).
Conclusion
Targeting risk factors for infection control significantly reduced the rate of CLABSI among high-risk infants in the NICU.
3.Efficacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, DoubleBlind, Active Control, Noninferiority, Multicenter, Phase 3 Study
Gwang Ha KIM ; Hang Lak LEE ; Moon Kyung JOO ; Hong Jun PARK ; Sung Woo JUNG ; Ok-Jae LEE ; Hyungkil KIM ; Hoon Jai CHUN ; Soo Teik LEE ; Ji Won KIM ; Han Ho JEON ; Il-Kwun CHUNG ; Hyun-Soo KIM ; Dong Ho LEE ; Kyoung-Oh KIM ; Yun Jeong LIM ; Seun-Ja PARK ; Soo-Jeong CHO ; Byung-Wook KIM ; Kwang Hyun KO ; Seong Woo JEON ; Jae Gyu KIM ; In-Kyung SUNG ; Tae Nyeun KIM ; Jae Kyu SUNG ; Jong-Jae PARK
Gut and Liver 2021;15(6):841-850
Background/Aims:
The mucoprotective drug rebamipide is used to treat gastritis and peptic ulcers. We compared the efficacy of Mucosta Ⓡ (rebamipide 100 mg) and its new formulation, AD-203 (rebamipide 150 mg), in treating erosive gastritis.
Methods:
This double-blind, active control, noninferiority, multicenter, phase 3 clinical trial randomly assigned 475 patients with endoscopically proven erosive gastritis to two groups: AD-203 twice daily or Mucosta Ⓡ thrice daily for 2 weeks. The intention-to-treat (ITT) analysis included 454 patients (AD-203, n=229; Mucosta Ⓡ , n=225), and the per-protocol (PP) analysis included 439 patients (AD-203, n=224; Mucosta Ⓡ , n=215). The posttreatment assessments included the primary (erosion improvement rate) and secondary endpoints (erosion and edema cure rates; improvement rates of redness, hemorrhage, and gastrointestinal symptoms). Drug-related adverse events were evaluated.
Results:
According to the ITT analysis, the erosion improvement rates (posttreatment) in AD-203-treated and Mucosta Ⓡ -treated patients were 39.7% and 43.8%, respectively. According to the PP analysis, the erosion improvement rates (posttreatment) in AD-203-treated and Mucosta Ⓡ -treated patients were 39.3% and 43.7%, respectively. The one-sided 97.5% lower limit for the improvement rate difference between the study groups was −4.01% (95% confidence interval [CI], –13.09% to 5.06%) in the ITT analysis and −4.44% (95% CI, –13.65% to 4.78%) in the PP analysis. The groups did not significantly differ in the secondary endpoints in either analysis. Twenty-four AD-203-treated and 20 Mucosta Ⓡ -treated patients reported adverse events but no serious adverse drug reactions; both groups presented similar adverse event rates.
Conclusions
The new formulation of rebamipide 150 mg (AD-203) twice daily was not inferior to rebamipide 100 mg (Mucosta Ⓡ ) thrice daily. Both formulations showed a similar efficacy in treating erosive gastritis.
4.Targeting Risk Factors for the Control of Central Line-Associated Bloodstream Infection in the Neonatal Intensive Care Unit: A Single Tertiary Center Experience
Jiyoon JEONG ; Yoojin KWUN ; Min-ju KIM ; Sang-Ho CHOI ; Euiseok JUNG ; Byong Sop LEE ; Ki-Soo KIM ; Ellen Ai-Rhan KIM
Neonatal Medicine 2021;28(3):116-123
Purpose:
The aim of this study was to estimate the effect of targeting risk factors for the control of central line-associated bloodstream infection (CLABSI) among high-risk infants in a tertiary neonatal intensive care unit (NICU).
Methods:
Infants admitted to the NICU and diagnosed with CLABSI from January to December 2013 were eligible for inclusion to the study. The CLABSI group (n=47) was matched in a 1:2 ratio to the control group (n=94) based on gestational age, birth weight, and Score for Neonatal Acute Physiology-II. Risk factors for CLABSI were identified using the Cox proportional hazard model, and analysis of the effect of these risk factors targeting infection control was performed.
Results:
The risk factors associated with CLABSI were prolonged central line dwell days (adjusted hazard ratio [HR], 1.028; 95% confidence interval [CI], 1.011 to 1.045; P=0.001), use of a silicone catheter (adjusted HR, 5.895; 95% CI, 1.893 to 18.355; P=0.002), surgical treatment (adjusted HR, 3.793; 95% CI, 1.467 to 9.805; P=0.006), and less probiotic supplementation (adjusted HR, 0.254; 95% CI, 0.068 to 0.949; P=0.042). By targeting these risk factors with a quality improvement initiative, the mean CLABSI incidence rate per 1,000 catheter-days decreased from 6.6 to 3.1 (P=0.004).
Conclusion
Targeting risk factors for infection control significantly reduced the rate of CLABSI among high-risk infants in the NICU.
5.Clinical Features and Awareness of Hand Eczema in Korea.
Jae Beom PARK ; Seung Ho LEE ; Kea Jeung KIM ; Ga Young LEE ; Jun Mo YANG ; Do Won KIM ; Seok Jong LEE ; Cheol Heon LEE ; Eun Joo PARK ; Kyu Han KIM ; Hee Chul EUN ; Sung Eun CHANG ; Kee Chan MOON ; Seong Hyun KIM ; Seong Jin KIM ; Byung Soo KIM ; Jun Young LEE ; Hyung Ok KIM ; Hoon KANG ; Min Geol LEE ; Soo Chan KIM ; Young Suck RO ; Joo Yeon KO ; Mi Youn PARK ; Myung Hwa KIM ; Jeong Hyun SHIN ; Hae Young CHOI ; Chang Kwun HONG ; Sung Yul LEE ; Hana BAK ; Sang Wook SON ; Ai Young LEE
Annals of Dermatology 2016;28(3):335-343
BACKGROUND: Hand eczema is one of the most common skin disorders and negatively affects quality of life. However, a large-scale multicenter study investigating the clinical features of patients with hand eczema has not yet been conducted in Korea. OBJECTIVE: To identify the prevalence of various hand diseases, which is defined as all cutaneous disease occurring in hands, and to investigate the clinical features of patients with hand eczema and the awareness about hand eczema in the general population and to compare the prevalence of hand eczema between health care providers and non-health care providers. METHODS: To estimate the prevalence of hand diseases, we analyzed the medical records of patients from 24 medical centers. Patients were assessed by online and offline questionnaires. A 1,000 from general population and 913 hand eczema patients answered the questionnaire, for a total of 1,913 subjects. RESULTS: The most common hand disease was irritant contact dermatitis. In an online survey, the lifetime prevalence of hand eczema was 31.2%. Hand eczema was more likely to occur in females (66.0%) and younger (20~39 years, 53.9%). Health care providers and housewives were the occupations most frequently associated with hand eczema. Winter (33.6%) was the most common season which people experienced aggravation. The 63.0% and 67.0% answered that hand eczema hinders their personal relationship and negatively affects daily living activities, respectively. CONCLUSION: Hand eczema is a very common disease and hinders the quality of life. The appropriate identification of hand eczema is necessary to implement effective and efficient treatment.
Activities of Daily Living
;
Dermatitis, Contact
;
Eczema*
;
Female
;
Hand*
;
Health Personnel
;
Humans
;
Korea*
;
Medical Records
;
Occupations
;
Prevalence
;
Quality of Life
;
Seasons
;
Skin
;
Surveys and Questionnaires
6.Online Registry for Nationwide Database of Current Trend of Helicobacter pylori Eradication in Korea: Interim Analysis.
Beom Jin KIM ; Hyun Soo KIM ; Hyun Joo SONG ; Il Kwun CHUNG ; Gwang Ha KIM ; Byung Wook KIM ; Ki Nam SHIM ; Seong Woo JEON ; Yun Jin JUNG ; Chang Hun YANG ; Ji Hyun KIM ; Tae Ho KIM ; Sang Gyun KIM ; Woon Geon SHIN ; Sun Moon KIM ; Sok Won HAN ; Jun Haeng LEE ; Kyung Ho KIM ; Sue K PARK ; Byung Joo PARK ; Joongyub LEE ; Jae G KIM
Journal of Korean Medical Science 2016;31(8):1246-1253
Eradication of Helicobacter pylori using first-line therapy is becoming less effective. Subjects who had been treated for H. pylori infection were prospectively enrolled through an on-line database registry from October 2010 to December 2012. Demographic data, detection methods, treatment indication, regimens, durations, compliance, adverse events, and eradication results for H. pylori infection were collected. Data of 3,700 patients from 34 hospitals were analyzed. The overall eradication rate of the first-line therapy was 73.0%. Eradication failure was significantly associated with old age, concomitant medication, and comorbidity. Regional differences in eradication rates were observed. The most common first-line therapy was proton pump inhibitor-based triple therapy (standard triple therapy, STT) for 7 days (86.8%). The eradication rates varied with regimens, being 73% in STT, 81.8% in bismuth-based quadruple therapy, 100% in sequential therapy, and 90.3% in concomitant therapy. The eradication rate in treatment-naïve patients was higher than that in patients previously treated for H. pylori infection (73.8% vs. 58.5%, P < 0.001). The overall eradication rate for second-line therapy was 84.3%. There was no statistical difference in eradication rates among various regimens. H. pylori eradication rate using STT is decreasing in Korea and has become sub-optimal, suggesting the need for alternative regimens to improve the efficacy of first-line therapy for H. pylori infection.
Adult
;
Age Factors
;
Aged
;
Anti-Bacterial Agents/*therapeutic use
;
Databases, Factual
;
Drug Therapy, Combination
;
Female
;
Helicobacter Infections/*drug therapy/microbiology
;
Helicobacter pylori/isolation & purification
;
Humans
;
Internet
;
Logistic Models
;
Male
;
Middle Aged
;
Prospective Studies
;
Proton Pump Inhibitors/*therapeutic use
;
Registries
;
Republic of Korea
;
Treatment Outcome
7.Online Registry for Nationwide Database of Current Trend of Helicobacter pylori Eradication in Korea: Interim Analysis.
Beom Jin KIM ; Hyun Soo KIM ; Hyun Joo SONG ; Il Kwun CHUNG ; Gwang Ha KIM ; Byung Wook KIM ; Ki Nam SHIM ; Seong Woo JEON ; Yun Jin JUNG ; Chang Hun YANG ; Ji Hyun KIM ; Tae Ho KIM ; Sang Gyun KIM ; Woon Geon SHIN ; Sun Moon KIM ; Sok Won HAN ; Jun Haeng LEE ; Kyung Ho KIM ; Sue K PARK ; Byung Joo PARK ; Joongyub LEE ; Jae G KIM
Journal of Korean Medical Science 2016;31(8):1246-1253
Eradication of Helicobacter pylori using first-line therapy is becoming less effective. Subjects who had been treated for H. pylori infection were prospectively enrolled through an on-line database registry from October 2010 to December 2012. Demographic data, detection methods, treatment indication, regimens, durations, compliance, adverse events, and eradication results for H. pylori infection were collected. Data of 3,700 patients from 34 hospitals were analyzed. The overall eradication rate of the first-line therapy was 73.0%. Eradication failure was significantly associated with old age, concomitant medication, and comorbidity. Regional differences in eradication rates were observed. The most common first-line therapy was proton pump inhibitor-based triple therapy (standard triple therapy, STT) for 7 days (86.8%). The eradication rates varied with regimens, being 73% in STT, 81.8% in bismuth-based quadruple therapy, 100% in sequential therapy, and 90.3% in concomitant therapy. The eradication rate in treatment-naïve patients was higher than that in patients previously treated for H. pylori infection (73.8% vs. 58.5%, P < 0.001). The overall eradication rate for second-line therapy was 84.3%. There was no statistical difference in eradication rates among various regimens. H. pylori eradication rate using STT is decreasing in Korea and has become sub-optimal, suggesting the need for alternative regimens to improve the efficacy of first-line therapy for H. pylori infection.
Adult
;
Age Factors
;
Aged
;
Anti-Bacterial Agents/*therapeutic use
;
Databases, Factual
;
Drug Therapy, Combination
;
Female
;
Helicobacter Infections/*drug therapy/microbiology
;
Helicobacter pylori/isolation & purification
;
Humans
;
Internet
;
Logistic Models
;
Male
;
Middle Aged
;
Prospective Studies
;
Proton Pump Inhibitors/*therapeutic use
;
Registries
;
Republic of Korea
;
Treatment Outcome
9.The Korean guideline for gastric cancer screening.
Hyun Ah PARK ; Su Youn NAM ; Sang Kil LEE ; Sang Gyun KIM ; Ki Nam SHIM ; Sang Min PARK ; Sun Young LEE ; Hye Seung HAN ; Yong Moon SHIN ; Kyoung Mee KIM ; Kyung Jae LEE ; Tae Yong LEE ; Il Ju CHOI ; Seong Sook HONG ; Jae Woo KIM ; Yoon Jae LEE ; Soo Young KIM ; Yeol KIM ; Won Chul LEE ; Il Kwun CHUNG
Journal of the Korean Medical Association 2015;58(5):373-384
Despite improvements in treatment modalities, gastric cancer is the second cause of mortality among Korean men and third among females in Korea. Korea implemented a gastric cancer screening program for the general population in 1999. However, the effectiveness and harms of gastric cancer screening using gastric endoscopy and upper gastrointestinal (UGI) series have not been fully evaluated. In an effort to evaluate the screening program, the Korean multidisciplinary expert committee for developing a gastric cancer screening guideline systematically reviewed the evidence regarding the benefits and harms of gastric cancer screening, and developed an evidence-based clinical guideline. There is 'low' level evidence that gastric cancer screening using gastric endoscopy or UGI series can reduce gastric cancer mortality for asymptomatic adults aged between 40 to 74 years. The benefits of gastric cancer screening using gastric endoscopy are substantially higher than its harms, while the benefits of screening with UGI series are moderately higher. We recommend that asymptomatic adults from 40 to 75 years of age undergo biannual gastric cancer screening using gastric endoscopy (recommendation B). Gastric cancer screening using UGI series in asymptomatic adults aged between 40 to 74 years may be recommended based on clinicians' judgment regarding the patient's risk and the patient's preference (recommendation C). There is insufficient evidence to assess the benefits and harms of gastric cancer screening for adults aged between 75 to 84 years (recommendation I). We recommend against gastric cancer screening for adults older than 85 years (recommendation D).
Adult
;
Early Detection of Cancer
;
Endoscopy
;
Female
;
Humans
;
Judgment
;
Korea
;
Male
;
Mass Screening*
;
Mortality
;
Stomach Neoplasms*
10.A Clinical and Epidemiological Study of Scabies in Korea: A Multicenter Prospective Study.
Song Youn PARK ; Joo Young ROH ; Jun Young LEE ; Do Won KIM ; Tae Jin YOON ; Woo Young SIM ; Kyu Suk LEE ; Young Chul KYE ; Ai Young LEE ; Moon Bum KIM ; Soyun CHO ; Kee Chan MOON ; Jun Mo YANG ; Eun So LEE ; Won Soo LEE ; Min Geol LEE ; Seok Don PARK ; Young Ho WON ; Bong Seok SHIN ; Chang Kwun HONG ; Jeunghoon LEE ; Tae Young YOON ; Kwang Joong KIM ; Young Suck RO ; Ki Ho KIM ; Hee Chul EUN
Korean Journal of Dermatology 2014;52(7):457-464
BACKGROUND: Scabies is an old and common contagious skin disease. The incidence of scabies has decreased through the economic growth of Korea. However, recent outbreaks in medical facilities have created a suspicion that the infection of scabies is an emerging public health problem. OBJECTIVE: We evaluated the epidemiological and clinical aspects of patients diagnosed with scabies in Korea. This prospective study follows the retrospective study already performed by the same authors in 2011. METHODS: A multicenter, prospective study of scabies was performed at 25 hospitals in Korea. We included 914 patients who were diagnosed with scabies. Microscopic examination revealed scabies mites or eggs, or clinical improvement after treatment. Patients were asked to provide information on scabies, especially regarding the contact source, and the physicians examined them. RESULTS: Of the participants, 432 patients were men and 482 were women. Patients aged younger than 10 years and 60~69 years were the most common groups. Scabies more commonly affected patients during the fall and winter. Of the patients, 68.0% were thought to be infected at their homes, followed by nursing homes or hospitals (25.7%), and 31.6% through contact with other patients or, occasionally, staff members, including caregivers. CONCLUSION: We confirmed that scabies is an emerging threat in institutions, especially medical facilities. In addition, we suggest that public and in-hospital education is essential to minimize the problems associated with scabies.
Caregivers
;
Disease Outbreaks
;
Economic Development
;
Education
;
Eggs
;
Epidemiologic Studies*
;
Epidemiology
;
Female
;
Humans
;
Incidence
;
Korea
;
Male
;
Mites
;
Nursing Homes
;
Ovum
;
Prospective Studies*
;
Public Health
;
Scabies*
;
Skin Diseases

Result Analysis
Print
Save
E-mail